Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears
Date
2015
Type:
ArtĆculo
item.page.extent
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
Biomed Central Ltd.
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
Chemotherapy has made an essential contribution to cancer treatment in recent decades despite its adverse effects. As cancer survivors have increased, concern about ex-patient lifespan has become more important too. Doxorubicin is an effective anti-neoplastic drug that produces a cardiotoxic effect. Cancer survivors who received doxorubicin became more vulnerable to cardiac disease than the normal population did. Many efforts have been made to prevent cardiac toxicity in patients with cancer. However, current therapies cannot guarantee permanent cardiac protection. One of their main limitations is that they do not promote myocardium regeneration. In this review, we summarize and discuss the promising use of mesenchymal stem cells for cardio-protection or cardio-regeneration therapies and consider their regenerative potential without leaving aside their controversial effects on tumor progression.
Description
Centro de Medicina Regenerativa
item.page.coverage.spatial
item.page.sponsorship
Citation
Stem Cell Research & Teraphy, June 2015,vol.6, nĀ°1, p.116
Keywords
Cardiomyopathy, Stem cell therapy, Doxorubicin, Cancer, Tumor